Jasper Guglielmi detachable coil embolization of intracranial aneurysms:a multicenter clinical trial

ZHANG Hong-qi,YANG Xin-jian,HUANG Qing-hai,ZHI Xing-long,ZHANG Peng,MU Shi-qing,LI You-xiang,ZHAO Wen-yuan,CHEN Tao,LIU Jian-min,WU Zhong-xue,LING Feng

DOI: https://doi.org/10.3969/j.issn.1672-5921.2008.10.004

2008-01-01

Abstract:Objective To validate the non-inferiority of Jasper Guglielmi detachable coil (GDC) developed by Achieva Medical Co. Ltd (Shanghai, China) in the embolization of intracranial aneurysms in clinical practice.Methods It was a prospective, multicenter, parallel, comparative clinical trial, and the regimen was approved by the Chinese State Food and Drug Administration (SFDA). A total 134 patients with non wide-necked intracranial aneurysms (Hunt-Hess grades 0-Ⅲ) were recruited. Among them, 64 patients used Jasper coils (trial group), and 70 used GDC and Sapphire coils (control group). The clinical performance of the coils (the convenience and reliability of the procedures in pushing, location releasing and withdrawing of delivery system) in the operation process and the success rate of implantation were evaluated during the procedures; the modified Rankin scale (mRS) scores were obtained at 1 and 6 months after the procedures; the results of angiography were assessed immediately after the procedures and at 6 months; the incidences such as the occurrence of adverse events, reoccurrence of subarachnoid hemorrhage, death and stroke were observed.Results The success rate of Jasper coil implantation in the trial group was 99.3% (344/345 coils), and it was 100% (304/304 coils) in the control group. There were no significant differences between the two groups in the success rate of coil implantation and clinical performance (P>0.05). No complications such as coil dislodgement, vasospasm, thrombosis, aneurysm rupture and vascular perforation were found. There were no significant differences between the two groups in mRS scores, the incidence of adverse events, the reoccurrence of subarachnoid hemorrhage, death and stroke (P>0.05). Angiography showed that the occlusion rate of lesions was 95.4±6.4% immediately after the procedures in the trial group. Six patients (9.4%) had incomplete occlusion, and 58 (90.6%) had complete occlusion. The occlusion rate of lesions was 94.8±5.5% after the procedures in the control group. Five patients (7.1%) had incomplete occlusion, and 65 (92.9%) had complete occlusion. There were no significant differences between the two groups (P>0.05). The follow-up angiographies were obtained in 40 patients in the trial group and 32 in the control group 6 months after the procedures. There were no significant differences between the two groups in the occlusion rate of aneurysms (P>0.05).Conclusion The clinical safety and efficacy of Jasper GDC for embolization of intracranial aneurysms are the same as those of the foreign products.